Core Insights - Moderna, Inc. announced data on two investigational influenza candidates to be presented at IDWeek 2025, highlighting advancements in mRNA-based vaccine technology [1] Group 1: Presentation Details - The Late-Breaking Oral Presentation 229 will focus on mRNA-1010, an mRNA-based influenza vaccine [1] - Data indicates that mRNA-1010 is safe and efficacious in adults aged 50 years [1] - The relative vaccine efficacy (rVE) of mRNA-1010 is compared to a licensed standard dose (SD) influenza vaccine [1]

Moderna's (NASDAQ: MRNA ) stock has continued to fall in 2025, despite a new vaccine approval and additional clinical readouts ahead. In January, I rated MRNA a sell, expecting the company would continue burning cash with little to show for itScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...

PresentationKyle Holen [Audio Gap] Some time with us. We're really excited about sharing with you some new data that we just shared earlier today on one of our assets, 4359 that's quickly becoming one of our newest late-stage assets similar to INT, which you've heard a lot about. I'm going to walk you through some of the INT data. And then we're just pleased to have some experts in the field that have joined us tonight to talk to you about melanoma and to talk to you about the data that was presented, the ...

Summary of Conference Call on Oncology Pipeline Company and Industry Overview - The conference call primarily discusses **Moderna's** oncology pipeline, focusing on their **Individualized Neoantigen Therapy (INT)** and **mRNA-4359** programs, which target melanoma and other cancers. The discussion includes insights from experts in the field of oncology, particularly regarding melanoma treatment advancements. Key Points and Arguments Pipeline Development - Moderna's pipeline has significantly expanded over the past few years, now including various cancer therapies such as **Individualized Neoantigen Therapy (INT)**, **cancer antigen therapies (CATs)**, and **T-cell engagers** [1][2][3] - The INT program is currently evaluating efficacy across multiple cancer types, including melanoma, lung cancer, renal cell carcinoma, and bladder cancer [3][4] Individualized Neoantigen Therapy (INT) - The INT program is unique in its approach, utilizing patient-specific tumor data to create personalized therapies. This involves sequencing tumor DNA and identifying unique mutations to predict immunogenic responses [4][5] - Recent data from a randomized phase II trial (P201) showed a **49% reduction in the risk of recurrence or death** and a **62% reduction in distant metastasis or death** for patients receiving INT combined with pembrolizumab compared to pembrolizumab alone [6][7] - The safety profile of INT was favorable, with no increase in immune-related adverse events compared to standard treatments [6][7] mRNA-4359 Program - mRNA-4359 targets both **PD-L1** and **IDO**, aiming to enhance T-cell responses against tumors. The mechanism is designed to address immune evasion and activate T-cells against cancer cells [21][24] - Preliminary data from an ongoing phase I-II trial indicated an **overall response rate of 24%** in heavily pretreated patients with refractory melanoma, which is notable given the patient population's history of resistance to prior therapies [32][33] - The safety profile of mRNA-4359 showed manageable adverse events, primarily mild symptoms such as injection site pain and fatigue, with no significant increase in high-grade immune-related adverse events [30][31][76] Melanoma Treatment Landscape - The discussion highlighted the evolving landscape of melanoma treatments, including the introduction of immune checkpoint inhibitors and combination therapies. Despite advancements, a significant unmet need remains for patients who do not respond to existing therapies [9][10][12] - The efficacy of combination therapies, such as anti-PD-1 and anti-CTLA-4, has been shown to be superior to single-agent therapies, but many patients still experience disease progression [11][12][15] Future Directions - Moderna plans to expand its clinical trials for mRNA-4359 to include combinations with other therapies, such as ipilimumab and nivolumab, and to explore its efficacy in non-small cell lung cancer [38] - The company is also investigating the potential of T-cell engagers and cell therapy enhancing programs, aiming to improve treatment outcomes for various cancers [39][40][41] Additional Important Insights - The conference emphasized the importance of biomarkers in identifying patients who may benefit from specific therapies, particularly in the context of precision medicine [33][34] - Ongoing translational research aims to better understand the mechanisms of action and patient responses to therapies, which is crucial for future drug development [51][52][53] This summary encapsulates the key discussions and findings from the conference call, highlighting Moderna's innovative approaches in oncology and the promising data emerging from their clinical trials.

Moderna Oncology Event October 17, 2025 © 2025 Moderna, Inc. All rights reserved. Forward-looking statements and important disclaimers This presentation being made by Moderna, Inc., and is intended solely for investors and financial analysts, and is not for promotional use. The information discussed relates to investigational candidates that have not been approved by regulatory authorities. No conclusions about the safety or efficacy of those investigational candidates should be drawn. Content is limited to ...

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update. ...

Key Points Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's working on a personalized cancer vaccine with Merck that's showing progress. 10 stocks we like better than Moderna › Can you believe that Moderna (NASDAQ: MRNA) was once worth more than $195 billion in 2021? Back then, the business looked on track to be the next big healthcare company. Then, ...

In the latest trading session, Moderna (MRNA) closed at $26.25, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. At the same time, the Dow added 0.44%, and the tech-heavy Nasdaq lost 0.76%. The biotechnology company's stock has climbed by 11.98% in the past month, exceeding the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. ...

Core Insights - The proverb "you have to spend money to make money" emphasizes the importance of R&D spending for companies aiming to increase profitability and market presence [1] R&D Importance - R&D is essential for innovation, leading to new or improved products, processes, and services, contributing to long-term economic growth [2] - Significant advancements, such as mRNA-based vaccines, are direct results of substantial R&D investments by companies like Pfizer, BioNTech, and Moderna [2] Historical Context - The features of modern smartphones, including touchscreens and GPS, are outcomes of decades of R&D by major tech companies like IBM, Apple, and Google [3] Leadership Perspective - Amazon's CEO emphasizes that R&D spending is critical for companies, particularly those with opportunities to enhance capabilities [4] - R&D investments can provide a competitive advantage through intellectual property and innovative service delivery, positioning companies as market leaders [5] Investment Strategy - Successful growth-oriented companies often allocate 10% or more of their revenue to R&D, though the specific percentage should be based on available opportunities and associated risks [6] - Companies must evaluate their potential for growth and market advantage to determine the appropriateness of heavy R&D investment [6]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...